Cadila Healthcare has informed the exchanges that the US Food and Drug Administration (FDA) has inspected the drug maker’s biologics manufacturing facility (Zydus Biologics) located at the Zydus Biotech Park in Ahmedabad, from August 14 to August 24, 2018.
At the end of the inspection, no observation (483) was issued. Investors will take note of this positive development. The stock of Cadila Healthcare closed at ₹401 on the BSE, up 2.6 per cent from the previous close.
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.